Artimplant Ab Annual Accounts Jan 1 - DEC 31, 2005.

STOCKHOLM, Sweden -- Artimplant Ab (STO:ARTIB):

--Net revenue increased by more than 70% and amounted 8,2 MSEK (4,8)

--Net profit of -36,2 MSEK (-42,4)

--Earnings per share of -0,73 SEK (-1,12 SEK)

--Four new development and license agreements signed with Small Bone Innovations during the fourth quarter

--Artelon(R) Surgical Suture received CE-mark and clearance for marketing in the USA

--Artelon(R) implant for rotator cuff reinforcement received CE-mark

--Distribution agreement for Artelon(R) Surgical Suture signed with ArthroCare Corporation

--Six out of the seven goals communicated in share issue prospectus in May 2005 were fulfilled

Events after the period

--Artelon(R) implant for rotator cuff reinforcement received clearance for marketing in the USA

--Artimplant established a small representation office in the US, Artimplant USA, Inc.

Upcoming information events

Interim report Jan-Mar 2006............... May 3, 2006

Interim report Jan-Jun 2006........... August 8, 2006

Interim report Jan-Sep 2006... .... November 9, 2006

Financial reports are available at www.artimplant.com simultaneously as distributed to the media. For information regarding business model, technology and products see Artimplant's annual report 2004, which is available at the Company's website.

Annual general meeting

The annual general meeting of shareholders will be held at 4 p.m. on May 3, 2006 at the Company headquarters. Registration will begin at 3:30 p.m. Shareholders who intend to participate must notify the Company no later than April 25, 2005, in one of the following ways:

--Send an e-mail to [e-mail]

--Send a fax to [phone]

--Call [phone]

--Write to Artimplant AB, AGM, Hulda Mellgrens gata 5, 421 32 Vastra Frolunda, Sweden.

Please include name, personal id. number or company id. number, address, telephone number and the number of shares in the share register as per April 21, 2005. To vote at the annual general meeting, a shareholder must be part of the share register maintained by VPC AB no later than April 21, 2005. Shareholders who have shares registered through a bank or brokerage, must temporarily register their shares in their own name to take part in the meeting. This should be done well in advance of the date specified above. The annual report will be published on the Company's web site no later than April 14, 2006, and will also be available at the Company headquarters. A copy of the annual report can be ordered by writing to the above address.

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Waymaker http://www.waymaker.net